Fundz

Who to call at Ixico PLC, and when

Fundz watches for the moments Ixico PLC starts buying, and tells you who to reach.

  • An alert the day Ixico PLC raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ixico PLC, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ixico PLC. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

IXICO secures £2.7m contract for imaging analysis in Huntington’s disease trial.

Nov 02, 2026

Contract Type

contract

LondonBiotechnologyHealth CareMedical

Description

IXICO has been awarded a £2.7m contract to provide imaging analysis for a late-stage Huntington’s disease drug trial. This global Phase 3 contract will generate revenue over the next six years, marking IXICO's second such contract for Huntington’s disease in a year.

Quick answer

IXICO secures £2.7m contract for imaging analysis in Huntington’s disease trial. (November 2, 2026). Ixico PLC is based in London, England, United Kingdom.

What agreement did Ixico PLC announce on November 2, 2026?
IXICO has been awarded a £2.7m contract to provide imaging analysis for a late-stage Huntington’s disease drug trial. This global Phase 3 contract will generate revenue over the next six years, marking IXICO's second such contract for Huntington’s disease in a year.
What does Ixico PLC do?
Ixico PLC is a London-based medical analytics company focused on accelerating the growth and global commercial reach of neurology technology platforms, addressing unmet clinical needs in neurological diseases, and...
Where is Ixico PLC based?
Ixico PLC is based in London, England, United Kingdom.
Which similar companies announced contracts around the same time?
Tilray Brands (November 1, 2026), Wildcat DX (November 4, 2026), JD Technologies Global (November 4, 2026) and Abbott Laboratories (November 5, 2026) also announced agreements within 45 days of Ixico PLC.

Source: Fundz verified event record.

Other recent agreements in Medical and Biotechnology

Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.

Company Information

Company

Ixico PLC

Location

London, England, United Kingdom

About

Ixico PLC is a London-based medical analytics company focused on accelerating the growth and global commercial reach of neurology technology platforms, addressing unmet clinical needs in neurological diseases, and developing and scaling product offerings across areas of drug development.

Related People

Mark
Likely contact at this company
••••••••@••••••••

See Mark's verified email →

Hannah
Likely contact at this company
••••••••@••••••••

See Hannah's verified email →

Grant
Likely contact at this company
••••••••@••••••••

See Grant's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Ixico PLC's next move

Learn about Strategic plan

Ixico PLC signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.